Preclinical Evaluation of the SARS-CoV-2 Mpro Inhibitor RAY1216

WuXi AppTec scientists contributed to a research article in the journal Nature Microbiology, which characterized a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro).  In a human ACE2 transgenic mouse model, this inhibitor (designated RAY1216) exhibited antiviral activities against SARS-CoV-2 comparable to those of nirmatrelvir, but with improved pharmacokinetics.

Access the Full Article Here
← Return to Resources

Related Content

Tuberculosis is the leading cause of death from an infectious disease and is caused by Mycobacterium tuberculosis (MTB). Inosine-5′-monophosphate dehydrogenase...

VIEW RESOURCE

Toll-like receptor 8 (TLR8) plays an essential role in human antiviral immunity by recognizing ssRNA of viruses. Upon activation by...

VIEW RESOURCE
← View all Infectious Diseases Resources
× peptide, amino acid

Contact An Expert Today!